A rating agency specializing in evaluating risky investments added Boston Scientific (NYSE:BSX) to its "Risk List," citing the ongoing fallout from its ill-starred Guidant buyout, its accounting and governance practices and how it pays its executives.
SweetSpot Diabetes Care Inc.
Boston Scientific Corp. (NYSE:BSX) landed FDA clearance for its Incepta, Energen and Punctua cardiac implants to treat heart failure and sudden cardiac death.
To go along with the new defibrillator systems, the Natick, Mass.-based med-tech titan is providing an extended warranty for the Incepta and Energen family of defibrillators.
More than 13,500 people are gathered in San Diego at the 71st annual scientific conference of the American Diabetes Assn. to lead the fight against diabetes, a disease that affects more than 26 million children and adults in the U.S., according to the ADA.
By 2020, the ADA estimates that more than half of adult Americans will have diabetes or pre-diabetes.
Already diabetes contributes to the deaths of more than 231,000 Americans each year, more than breast cancer and AIDS combined.